In the January–March 2015 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory K. Bell and other industry experts discuss managing product liability in the pharma and healthcare sector. To read the article, click the link below.
Strategic implications for the 340B Rebate Model Pilot Program
These entities receive discounts on all eligible covered outpatient drugs. The program has expanded substantially over the years, with the number of covered...
